Relationship between gonadotropin releasing hormone agonist dosage andin vitrofertilization outcome
Authors:
- 1 January 2004
- journal article
- research article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 18 (2) , 69-73
Abstract
A prospective study in 132 women undergoing in vitro fertilization was performed in order to assess whether lower doses of gonadotropin releasing hormone agonists (GnRH-a) may ensure adequate oocyte retrieval and pregnancy rate, without pituitary oversuppression. Fortyfive patients received subcutaneous tryptorelin depot (Decapeptyl 3.75, IPSEN SpA), 41 received subcutaneous tryptorelin acetate daily (Decapeptyl 0.1 mg, IPSEN SpA) and 46 received 0.05 mg tryptorelin acetate daily from day 21 of the cycle. From day 3 of the new cycle, if the estradiol levels were < 30 pg/ml, patients received two or three ampules of gonadotropin daily. In the group receiving subcutaneous tryptorelin acetate depot, the mean number of total gonadotropin ampules was significantly higher (p<0.05), otherwise estradiol levels and the number of oocytes retrieved, fertilized and cleaved were significantly lower (p<0.05). Pituitary oversuppression induced by GnRH-a causes an increase in the gonadotropin requirement for assisted reproductive techniques (ART) and a reduction in the number of oocytes retrieved and fertilized. There is a high risk of oversuppression in normal-weight or underweight women, because there is greater bioavailability of the peptide, hence elevated circulating levels of GnRH-a. Thus, ovarian stimulation in ART cycles depends on many factors, not least the identification of the best GnRH-a dose.Keywords
This publication has 12 references indexed in Scilit:
- Cessation of Low-Dose Gonadotropin Releasing Hormone Agonist Therapy Followed by High-Dose Gonadotropin Stimulation Yields a Favorable Ovarian Response in Poor RespondersJournal of Assisted Reproduction and Genetics, 2002
- Efficacy and safety of long-acting GnRH agonists inin vitrofertilization and embryo transferHuman Fertility, 2001
- Does Body Mass Index of Infertile Women Have an Impact on IVF Procedure and Outcome?Journal of Assisted Reproduction and Genetics, 2000
- Direct ovarian effects and safety aspects of GnRH agonists and antagonistsHuman Reproduction Update, 2000
- Role of Gonadotropin-Releasing Hormone as an Autocrine Growth Factor in Human Ovarian Surface Epithelium1Endocrinology, 2000
- Extremes of body mass do not adversely affect the outcome of superovulation and in-vitro fertilizationHuman Reproduction, 1999
- Recombinant luteinizing hormone in ovarian hyperstimulation after stimulation failure in normogonadotropic womenGynecological Endocrinology, 1999
- The ovarian response as a predictor for successful in vitro fertilization treatment after the age of 40 yearsFertility and Sterility, 1996
- The luteinizing hormone surge—the final stage in ovulation induction: modern aspects of ovulation triggeringFertility and Sterility, 1995
- The Effect of Leuprolide Acetate on Ovulation Induction with Human Menopausal Gonadotropins in Polycystic Ovary Syndrome*The Journal of Clinical Endocrinology & Metabolism, 1987